Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Matthew Gantz | M | 59 |
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 3 years |
| Jeffrey Aronin | M | 56 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 6 years |
| Mick Farrell | M | 51 | 10 years | |
| Michael Michelson | M | 72 | 9 years | |
| David Kunz | M | - | 8 years | |
| Jeffrey G. Hesselberg | M | 65 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 4 years |
| Antonio Gracias | M | 53 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 6 years |
| Mary Spellman | M | 62 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 4 years |
| Andrea Kistner | F | - |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 4 years |
| Sang Yi | M | 61 | 11 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Florin | M | 60 | 5 years | |
| Amit Singh Dang | M | 43 | 2 years | |
| Gary Branning | M | 70 | 4 years | |
| Harmel Rayat | M | 63 | 8 years | |
| David Gionco | M | 63 | - | |
| John M. Maslowski | M | 49 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 5 years |
| Raymond Krauss | M | 62 | 3 years | |
| Paul Bisaro | M | 63 | 4 years | |
| Linda K. Ferrell | M | 64 |
Illinois State University
| 6 years |
| Hisham bin Zainal Mokhtar | M | 61 |
Illinois State University
| 6 years |
| Jeffrey Rhodes | M | 48 | 1 years | |
| Norman D. Finch | M | 59 | 8 years | |
| Gregory Licholai | M | 59 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 2 years |
| Jeet S. Sidhu | M | 51 | 2 years | |
| Joseph A. Cucolo | M | 63 | 3 years | |
| Marc N. Kingry | M | 61 |
Illinois State University
| 5 years |
| Marc Casper | M | 56 | 4 years | |
| James T. Crines | M | 64 | 20 years | |
| R. Graf | M | 59 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
| Robert Reardon | M | - |
Illinois State University
| 3 years |
| Mark J. Burns | M | - |
Illinois State University
| 4 years |
| Jay Blunk | M | - |
Illinois State University
| 4 years |
| Ken Cady | M | - |
Illinois State University
| 4 years |
| Steve Glover | M | - |
Illinois State University
| 4 years |
| Amir Tavakkol | M | 69 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 1 years |
| Kurt Gwillim | M | - |
Illinois State University
| 4 years |
| Kirsten Lynch | F | 56 |
Illinois State University
| 4 years |
| Steve Denault | M | - |
Illinois State University
| 4 years |
| Amit S. Dang | M | 42 | 2 years | |
| Sylvia Mcbrinn | F | 71 |
Andrx Laboratories, Inc.
 Andrx Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Andrx Laboratories, Inc. was a specialty pharmaceuticals company that was acquired by Watson Pharmaceuticals in November 2006. It engaged in the development and commercialization of controlled-release branded pharmaceuticals and generics. The company was founded in 1995 and was headquartered in Fort Lauderdale, FL. | 1 years |
| Michael Marcheschi | M | - |
Illinois State University
| 4 years |
| Andrew LaFrence | M | 61 |
Illinois State University
| 4 years |
| John Koconis | M | 54 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 3 years |
| Stephen Deitsch | M | 52 | 12 years | |
| Michelle M. Hermann | F | - |
Illinois State University
| 4 years |
| Katarzyna Mazur-Hofsaess | M | 60 | 5 years | |
| Scott Elliott | M | - |
Illinois State University
| 4 years |
| Daryl Roy Dagit | M | - |
Illinois State University
| 3 years |
| Hamzah bin Mahmood | M | 62 |
Illinois State University
| 4 years |
| Yuliya Aslan | F | - | 5 years | |
| Jennifer M. Wagner | F | - |
Illinois State University
| 13 years |
| Connie Kelly | F | - |
Illinois State University
| 4 years |
| Michael A. Connolly | M | - |
Illinois State University
| 4 years |
| Doug Lenhart | M | - |
Illinois State University
| 4 years |
| Gregory MacMichael | M | 68 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | - |
| Shane Michael Jent | M | - |
Illinois State University
| 4 years |
| Timothy Theriault | M | 63 |
Illinois State University
| 4 years |
| Tim McGrath | M | - |
Illinois State University
| 4 years |
| Terence Rogers | M | 64 |
Illinois State University
| 4 years |
| James B. Durkin | M | 63 |
Illinois State University
| 4 years |
| Prabodh Kumar Kantilal H. Sheth | M | 61 |
Illinois State University
| 4 years |
| Audrey M. Beckman | F | - | 2 years | |
| Jong-Beom Hwang | M | 63 |
Illinois State University
| 1 years |
| Robert Drobny | M | - |
Illinois State University
| 4 years |
| Christopher Catani | M | - |
Illinois State University
| 4 years |
| Mike Millard, MBA | - | - |
Illinois State University
| 4 years |
| Michael Bucek | M | - |
Illinois State University
| 4 years |
| Robert Walter Roche | M | 61 |
Illinois State University
| 4 years |
| William J. Kenealy | M | 61 |
Illinois State University
| 4 years |
| Rick A. Henson | M | 74 | 1 years | |
| Cheri R. Mazza | M | 65 |
Illinois State University
| 1 years |
| Scott Friel | M | - |
Illinois State University
| 1 years |
| Ronald Knutson | M | 60 |
Illinois State University
| 4 years |
| Rebecca Whitney | F | - | 7 years | |
| William J. Doyle | M | 60 |
Illinois State University
| 4 years |
| Clifford T. Bacsik | M | - | 1 years | |
| Jeffery A. McCaulley | M | 58 | 6 years | |
| Gregory M. Delaney | M | - |
Illinois State University
| 4 years |
| Michael J. Sheyker | M | - |
Illinois State University
| 4 years |
| Roger A. Albrecht | M | - |
Illinois State University
| 4 years |
| Pat Tschosik | M | - |
Illinois State University
| 4 years |
| Bruno A. Melzi | M | 76 | 23 years | |
| James Turner | M | - |
Illinois State University
| 4 years |
| James F. Lynch | M | - | - | |
| Dale E. Quayle | M | - |
Illinois State University
| 4 years |
| W. Middlekauff | M | 63 |
Castle Creek Biosciences, Inc.
Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Castle Creek Biosciences, Inc. engages in the research and development of gene therapies for patients with rare and genetic diseases. It offers treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and localized Scleroderma; and topical ointment for Epidermolysis Bullosa Simplex. The company was founded by Jeffrey S. Aronin in September 2018 and is headquartered in Exton, PA. | 1 years |
| Tim Hoerr | M | - |
Illinois State University
| 4 years |
| Kathryn A. Cole | F | 59 | 5 years | |
| Samuel L. Persico | M | - |
Illinois State University
| 4 years |
| Lawrence A. Gyenes | M | 73 | 1 years | |
| Robin T. Barney | F | 62 | 1 years | |
| Mike Millard | M | - |
Illinois State University
| 4 years |
| Stephen A. Johnson | M | - |
Illinois State University
| 4 years |
| Gary W. Masso | M | - |
Illinois State University
| 4 years |
| Carl Soderstrom | M | - |
Illinois State University
| 4 years |
| Neal West | M | 65 |
Illinois State University
| 4 years |
| Rodney D Perry | M | - |
Illinois State University
| 5 years |
| Stephen H. L. Ooi | M | 70 | 29 years | |
| Robert Zmudka | M | - |
Illinois State University
| 4 years |
| Brian Vargo | M | - |
Illinois State University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gregory Wujek
- Personal Network